Amid the continuously increasing global incidence of diabetes, glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as a cornerstone in type 2 diabetes treatment, demonstrating remarkable efficacy in glycemic control and cardiovascular risk reduction [1, 2]. Here, GLP1R is linked to diabetes mellitus.